The study, published this week by the National Bureau of Economic Research, runs counter to the widespread belief that a widening gap between rich and poor has made it harder to climb the economic ladder.
Democratic and Republican lawmakers alike have expressed alarm over what had been seen as diminishing opportunities for economic advancement through hard work and ingenuity.
Instead, the study found that 9% of children born in 1986 to the poorest 20% of households were likely to climb into the top 20% ��little-changed from 8.4% for such children born in 1971.
Hot Quality Stocks To Own Right Now: Walter Energy Inc.(WLT)
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry primarily in the United States. The company also produces thermal and industrial coal, anthracite, metallurgical coke, coal bed methane gas, and other related products. It principally serves electric utility and industrial customers. The company was formerly known as Walter Industries, Inc. and changed its name to Walter Energy, Inc. in April 2009. Walter Energy, Inc. was founded in 1946 and is headquartered in Birmingham, Alabama.
Advisors' Opinion:- [By Jon C. Ogg]
Walter Energy Inc. (NYSE: WLT) has been battered and is into metallurgical coal for the steel industry, as well as thermal and industrial coal and other coal products. It also just raised $450 million in senior secured notes, which originally was�going to be a $350 million offering. Goldman Sachs raised its rating to Neutral from Sell and raised its target to $15 from $10. This new target offers only modest upside from the $14.55 closing price, but note that the consensus analyst price target was $18 before this upgrade and raised target price.
Hot Quality Stocks To Own Right Now: Provectus Pharmaceuticals Inc (PVCT)
Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.
PV-10
As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.
PH-10
The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.
Over-the-Counter Pharmaceuticals
The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.
The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.
Advisors' Opinion:- [By Jake L'Ecuyer]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
- [By Luke Jacobi]
Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.
10 Best Solar Stocks To Own Right Now: The Cushing MLP Total Return Fund(SRV)
Cushing MLP Total Return Fund is a closed-end mutual fund launched by Swank Capital, LLC. The fund is managed by Swank Energy Income Advisors L.P. It invests in the public equity and fixed income markets across the globe with a focus in United States. The fund typically invests in MLPs, Other Natural Resource Companies, and global commodities. It primarily invests in the securities of MLPs, other equity securities, debt securities, and securities of non-U.S. issuers employing a fundamental analysis. Cushing MLP Total Return Fund was formed on May 23, 2007 and is domiciled in Dallas.
Advisors' Opinion:- [By Robert Rapier]
As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.
- [By Robert Rapier]
As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.
Hot Quality Stocks To Own Right Now: Bellway PLC (BWY)
Bellway p.l.c. is a United Kingdom-based holding company, owning subsidiary undertakings, which is engaged principally in housebuilding in the United Kingdom. The Company�� subsidiaries include Bellway Homes Limited, Bellway Properties Limited, Bellway (Services) Limited, Litrose Investments Limited, Bellway Financial Services Limited, Bellway Housing Trust Limited and The Victoria Dock Company Limited. Advisors' Opinion:- [By Sofia Horta e Costa]
Bellway Plc (BWY) added 1.4 percent after the homebuilder said reservations in the past four months rose 31 percent as buyers had greater access to mortgages. Elan (ELN) Corp. jumped to a 10-month high in Dublin after Royalty Pharma increased its offer for the Irish drugmaker to as much as $6.7 billion. BT Group increased 3.7 percent as Barclays Plc recommended investors buy shares of the U.K.�� largest fixed-line company.
- [By Sofia Horta e Costa]
Persimmon dropped 4.3 percent to 1,061 pence, while Bellway Plc (BWY) declined 3.1 percent to 1,262 pence. Bovis Homes Group Plc slipped 2.7 percent to 712 pence. Chancellor of the Exchequer George Osborne and the Bank of England will reassess the Help-to-Buy program, which allows the purchase of homes with a deposit as small as 5 percent, every September from 2014, the Treasury said.
Hot Quality Stocks To Own Right Now: RDA Microelectronics Inc.(RDA)
RDA Microelectronics, Inc., a fabless semiconductor company, designs, develops, and markets radio-frequency and mixed-signal semiconductors for cellular, broadcast, and connectivity applications. Its products include power amplifiers, transceivers and front-end modules, FM radio receivers and transmitters, set-top box tuners, analog mobile television receivers, walkie-talkie transceivers, LNB satellite downconverters, and Bluetooth system-on-chips for mobile handsets. The company?s products also comprise GSM/EDGE power amplifier modules, GSM transceivers, TD-SCDMA transceivers, SCDMA transceivers, 3G switch modules, GSM power amplifier and switch modules, PHS transceivers, TD-SCDMA/GSM dual-mode transceivers, and radio frequency switches; DVB-T tuners, DVB-S and DVB-S2 satellite tuners, analog mobile television receiver system-on-chips, and FM radio receivers with radio data system; and Bluetooth + FM system-on-chips for mobile handsets and walkie-talkie transceivers for professional applications. Its products are incorporated into mobile handsets, set-top boxes, MP3 players, and other wireless and consumer electronic devices. RDA Microelectronics sells its products through distributors in the People?s Republic of China, southeast Asia, India, the Middle East, Africa, the Russian Federation, and Latin America. The company was founded in 2004 and is headquartered in Shanghai, the People?s Republic of China.
Advisors' Opinion:- [By Lauren Pollock]
RDA Microelectronics Inc.(RDA) has received a takeover proposal from Shanghai Pudong Science & Technology Investment Co. valuing the Chinese semiconductor company at $745 million. PDSTI, a state-owned investment company, offered to buy RDA for $15.50 an American depositary share, a 12% premium to RDA’s closing price Thursday. RDA shares were halted premarket ahead of the news.
- [By Luke Jacobi]
RDA Microelectronics (NASDAQ: RDA) shot up 11.96 percent to $15.54 after the company received a non-binding acquisition proposal.
Finish Line (NASDAQ: FINL) got a boost, shooting up 9.02 percent to $24.41 after the company reported a 6.1 percent rise in its fiscal second-quarter earnings.
- [By Anna Prior]
RDA Microelectronics Inc.(RDA) agreed to be acquired by a unit of Chinese state owned Tsinghua Holdings Co. in a deal estimated at $910 million. RDA Microelectronics shareholders will receive $18.50 per American depositary share, a 5.5% premium to Friday’s close.
Hot Quality Stocks To Own Right Now: McMoRan Exploration Company (MMR)
McMoRan Exploration Co. engages in the exploration, development, production, and marketing of oil and natural gas in the shallow waters of the Gulf of Mexico and onshore in the Gulf Coast area of the United States. It is involved in lifting oil and natural gas to the surface; and gathering, treating, and processing hydrocarbons to extract liquids, such as ethane, propane, butane, and natural gasolines from natural gas. The company also provides exploration and production technologies, including the incorporation of 3-D seismic interpretation, offshore drilling to total depths, and horizontal drilling. As of December 31, 2012, it owned or controlled interests in 1,003 oil and gas leases in the Gulf of Mexico, and onshore Louisiana and Texas covering approximately 511,000 net acres. The company had estimated proved oil and natural gas reserves totaling 219.9 billion cubic feet equivalent. McMoRan Exploration Co. was founded in 1994 and is headquartered in New Orleans, Louisi ana.
Advisors' Opinion:- [By David Smith]
The pending purchases
Aside from its current core metals operations, Freeport is in the process of acquiring a pair of independent oil and gas producers, Plains Exploration & Production (NYSE: PXP ) and McMoRan Exploration (NYSE: MMR ) . In December, Freeport announced that it would pay 0.6531 shares of its common stock and $25 in cash for each outstanding share of Plains. In addition, for McMoRan it stated that it would pay $14.75 in cash and 1.15 units of a royalty trust that will hold a 5% overriding royalty interest in McMoRan's shallow water and ultra-deepwater prospects. - [By David Smith]
As we move into June, the company's attention is being directed to the combination of starting its huge Grasberg copper and gold facility in Indonesia, following a pair of accidents, and buttoning up its purchase of Houston-based energy producer Plains Exploration and Production Company. At the same time, its preparing to close on its planned acquisition of McMoRan Exploration (NYSE: MMR ) , an event that's expected to occur early next week.
- [By Rich Duprey]
While there was a lot of grousing, the miner was returning to its roots as a multiline resources company -- it will also be purchasing McMoRan Exploration (NYSE: MMR ) , a driller it had spun out in the 1990s -- after a series of mishaps and deadly accidents at its huge Grasberg mine, it could be the drilling operations that Freeport relies upon to see it through.
Hot Quality Stocks To Own Right Now: AngioDynamics Inc.(ANGO)
AngioDynamics, Inc. designs, develops, manufactures, and markets various therapeutic and diagnostic devices that enable interventional physicians to treat PVD, tumors, and other non-coronary diseases. The company operates in two divisions, Vascular and Oncology/Surgery. The Vascular division provides venous products, including VenaCure EVLT laser systems and Sotradecol; angiographic products and accessories comprising angiographic catheters, entry needles, guidewires, and fluid management products; percutaneous transluminal angioplasty dilation balloon catheters, such as WorkHorse, WorkHorse II, and Profiler to open blocked blood vessels and dialysis access sites; drainage products consisting of the total abscession general, biliary, and nephrostomy drainage catheters; and thrombolytic products that include pulsespray infusion and unifuse thrombolytic catheters, and speedlyser to deliver thrombolytic agents. It also offers micro access sets that provide interventional phys icians a smaller introducer system for minimally-invasive procedures; Benephit, a therapeutic approach to deliver drugs directly to the kidneys; and various dialysis catheters, which comprise DuraMax, Schon, Evenmore, Dura-Flow, SCHON XL, LifeJet, and Centros dialysis catheters. In addition, this division provides PICC products consisting of Morpheus CT PICC, Morpheus CT PICC insertion kits, and Morpheus smart PICC; port products and accessories, including Vortex, SmartPort, and LifeGuard; and central venous catheter products. The Oncology/Surgery division offers radiofrequency ablation, embolization, and nanoknife products. The company markets its products to interventional radiologists, vascular surgeons, and surgical oncologists through a direct sales force in the United States and through a combination of direct sales and distributor relationships internationally. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Advisors' Opinion:- [By Wallace Witkowski]
In other earnings reports, shares of AngioDynamics Inc. (ANGO) �rose 4.1% to $18.71 on moderate volume after the medical device maker reported adjusted fiscal second-quarter earnings of 14 cents a share on revenue of $88.6 million, while analysts expected 7 cents a share on revenue of $87.5 million. For fiscal 2014, AngioDynamics sees revenue of $349 million to $353 million, while analysts expect $350.7 million.
- [By Seth Jayson]
AngioDynamics (Nasdaq: ANGO ) is expected to report Q4 earnings on July 11. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AngioDynamics's revenues will expand 49.9% and EPS will wither -40.0%. - [By Lauren Pollock]
AngioDynamics Inc.(ANGO) swung to a modest fiscal second-quarter loss but achieved break-even per-share results as the medical-device maker’s revenue improved more than expected, pushing shares up 6.5% to $19.15 premarket.
Hot Quality Stocks To Own Right Now: Trovagene Inc (TROV)
TrovaGene, Inc. (TrovaGene), incorporated on April 26, 2002, is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�� urine-based test addresses market needs, such as women�� healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform.
On January 18, 2011, the Company entered into an asset purchase agreement pursuant to which the Company acquired a hybridoma able to produce a monoclonal antibody targeting the NPM1 biomarker. On February 8, 2011, the Company entered into a sublicense agreement with MLL Munchner Leukamielabor (MLL). In July, 2011, the Company entered into a sublicense agreement with Fairview Health Services (Fairview) for NPM1 patent rights.
In October 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to a specific gene mutation with respect to chronic lymphoblastic leukemia. On December 12, 2011, the Company entered into a license agreement pursuant to which the Company licensed the patent rights to hairy cell leukemia biomarkers. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).
Advisors' Opinion:- [By David Goodboy]
Fortunately, diagnostic issues may soon be a thing of the past. Several publicly traded companies are currently making great strides in the field of medical diagnostics, and my favorite company right now in that arena is TrovaGene (Nasdaq: TROV).
- [By Daniel Lauchheimer]
In the past few weeks, I wrote two articles about TrovaGene (TROV) -- one detailing the history of the DNA market generally and the molecular diagnostics -- and TROV's place therein -- market specifically, and the second detailing the company's internal valuation. In this article, I will value TROV on an external, relative basis. Specifically, I will compare TROV to another molecular diagnostics company, Exact Sciences (EXAS), and try to show that while the market seems to have given EXAS a fair shake, it has not done the same for TROV. I will prove this argument by looking at both companies' addressable markets, and their respective progress at bringing the products to market. However, before we take this deep dive into both companies, I will take a moment to review each of the companies' products, so we have a strong background before turning to the deeper analysis.
- [By Roberto Pedone]
TrovaGene (TROV) is a development stage molecular diagnostic company focused on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. This stock closed up 6% to $10.02 in Friday's trading session.
Friday's Volume: 712,000
Three-Month Average Volume: 183,106
Volume % Change: 294%From a technical perspective, TROV ripped higher here into all-time high territory with heavy upside volume. This stock has been uptrending strong for the last month and change, with shares soaring higher from its low of $5.75 to its new all-time high of $10.20. During that move, shares of TROV have been making mostly higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by bullish upside volume flows.
Traders should now look for long-biased trades in TROV as long as it's trending above its recent breakout level of $8.83, and then once it sustains a move or close above its all-time high of $10.20 with volume that hits near or above 183,106 shares. If we get that move soon, then TROV will set up to enter new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $13 to $15.
Hot Quality Stocks To Own Right Now: International Rectifier Corporation (IRF)
International Rectifier Corporation designs, manufactures, and markets power management semiconductors worldwide. The company operates through six segments: Power Management Devices, Energy Saving Products, Automotive Products, Enterprise Power, HiRel, and Intellectual Property. The Power Management Devices segment provides power metal oxide semiconductor field effect transistors (MOSFETs), FETKYs, and DirectFETs for power supply, data processing, telecommunications, industrial, and commercial battery-powered systems. The Energy Saving Products segment provides analog high voltage integrated circuits (HVICs), insulated gate bipolar transistors (IGBTs) platforms, digital control ICs, and IRAM integrated power modules for motor control appliances, industrial automation, lighting and display, audio, and video applications. The Automotive Products segment offers HVICs, intelligent power switch ICs, power MOSFETs, IGBTs, diodes, and advanced power modules for various automotive applications. The Enterprise Power segment offers DirectFET discrete products, digital PWM controllers, power monitoring products, voltage regulators, low voltage ICs, and PowIRstages primarily for applications in servers, storage, routers, switches, infrastructure equipment, notebooks, graphic cards, and gaming consoles. The HiRel segment provides RAD-hard discretes, RAD-hard ICs, power management modules, DC-DC converters, and high temperature converters for satellites and space exploration vehicles, military hardware, and other high reliability applications. The Intellectual Property segment sells and licenses technologies and manufacturing process know-how. The company was founded in 1947 and is headquartered in El Segundo, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on International Rectifier (NYSE: IRF ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment